Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: Two case reports

European Review for Medical and Pharmacological Sciences

Volumn 16, Issue 7, 2012, Pages 952-957

  Agrillo, A ^a   Siniscalchi, Enrico Nastro ^a   Facchini, A ^a   Filiaci, F ^a   Ungari, C ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antiangiogenic; Bisphosphonates; Jaws; Osteonecrosis; Sunitinib

Indexed keywords

BETA LACTAM; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; NAVELBINE; PENICILLIN G; RECOMBINANT ALPHA2A INTERFERON; SUNITINIB; ZOLEDRONIC ACID;

AGED; ANTIBIOTIC THERAPY; BONE ATROPHY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATALITY; GINGIVITIS; HUMAN; IMMUNOTHERAPY; JAW DISEASE; JAW OSTEONECROSIS; KIDNEY CARCINOMA; MALE; MANDIBLE RESECTION; MASTICATORY MUSCLE; MAXILLA SINUSITIS; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OZONE THERAPY; REVIEW; SWELLING; TREATMENT DURATION;

AGED; ANGIOGENESIS INHIBITORS; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; DIPHOSPHONATES; DISEASE PROGRESSION; FATAL OUTCOME; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; NEPHRECTOMY; PYRROLES; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84864186073     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. WANG J, GOODGER NM, POGREL MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003; 61: 1104-1107.
2. BOUQUOT JE, MCMAHON RE. Neurophatic pain in maxillofacial osteonecrosis. J Oral Maxillofac Surg 2000; 58: 1003-1020.
3. REGEZI JA, SCIUBBA JJ. Chronic osteomyelitis In: Regezi JA, Sciubba JJ, eds. Oral pathology. 3rd ed. Philadelphia:WB Saunders, 1999; p. 389.
4. OLSON KB, HELLIE CM, PIENTA KJ. Osteonecrosis of the jaw in patient with hormone refractary prostate cancer treated with Zoledronic acid. Urology 2005; 66: 658.
5. MIGLIORATI CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003; 21: 4253-4254.
6. ORRIS IR, KEY ML, COLSTON KW, ARNETT TR. Inhibition of osteoclast function in vitro by aminobisphophonates. J Cell Biochem 2009; 106: 109-118.
7. WALTER C, KLEIN MO, PABST A, AL-NAWAS B, DUSCHNER H, ZIEBART T. Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Investig 2010; 14: 35-41.
8. LANDESBERG R, COZIN M, CREMERS S, WOO V, KOUSTENI S, SINHA S, GARRETT-SINHA L, RAGHAVAN S. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 2008; 66: 839-847.
9. NASTRO SINISCALCHI E, CUTRONEO G, CATALFAMO L, SANTORO G, ALLEGRA A, OTERI G, CICCIÙ D, ALONCI A, PENNA G, MUSOLINO C, SAVERIO DE PONTE F, ANASTASI G, FAVALORO A. Immunohistochemial evaluation of sarcoglycans and integrins in gingival epithelium of multiple myeloma patients with bisphosphonate- induced osteonecrosis of the jaw. Oncol Rep 2010; 24: 129-134.
10. HANSEN T, KUNKEL M, WEBER A, JAMES KIRKPATRICK C. Osteonecrosis of the jaws in patients treated with bisphosphonates. Histomorphologic analysis in comparison with infected osteo- radionecrosis. J Oral Pathol Med 2006; 35: 155-160.
11. SCAVELLI C, DI PIETRO G, CIRULLI T, COLUCCIA M, BOCCARELLI A, GIANNINI T, MANGIALARDI G, BERTIERI R, COLUCCIA AM, RIBATTI D, DAMMACCO F, VACCA A. Zoledronic acid affects over-Angiogenic phenotype of endothelial cells in patients with multiple myeloma. Mol Cancer Ther 2007; 6: 3256-3262.
12. KOCH FP, WALTER C, HANSEN T, JÄGER E, WAGNER W. Osteonecrosis of the jaw related to sunitinib. Oral Maxillofac Surg 2011; 15: 63-66.
13. HOEFERT S, EUFINGER H. Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 110: 463-469.
14. CHRISTODOULOU C, PERVENA A, KLOUVAS G, GALANI E, FALAGAS ME, TSAKALOS G, VISVIKIS A, NIKOLAKOPOULOU A, ACHOLOS V, KARAPANAGIOTIDIS G, BATZIOU E, SKARLOS DV. Combination of bisphosphonates and antiangiogenetic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009; 76: 209-211.
15. AYLLON J, LAUNAY-VACHER V, MEDIONI J, CROS C, SPANO JP, OUDARD S. Osteonecrosis of the jaw under bisphonates and antiangiogenic therapies: cumulative toxicity profile? Ann Oncol 2009; 20: 600-601.
16. BRUNELLO A, SAIA G, BEDOGNI A, SCAGLIONE D, BASSO U. Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone 2009; 44: 173-175.
17. GUARNIERI V, MILES D, ROBERT N, DIÉRAS V, GLASPY J, SMITH I, THOMSSEN C, BIGANZOLI L, TARAN T, CONTE P. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 2010; 122: 181-188.
18. RUGGIERO SL, DODSON TB, ASSAEL LA, LANDESBERG R, MARX RE, MEHROTRA B; AMERICAN ASSOCIATION OF ORAL AND MAXILLOFACIAL SURGEONS. Americian Association of Oral Maxillofacial Surgeons: Position paper on bisphosphonate-related osteonecrosis of the jaws-2009 Update. J Oral Maxillofac Surg 2009; 67: 2-12.
19. RUGGIERO SL, MEHROTRA B, ROSENBERG TJ, ENHGROFF SL. Osteonecrosis of the jaws associated with the use of bisphosphonates. A review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-534.
20. DECKERS MM, VAN BEEK ER, VAN DER PLUIJM G, WETTERWALD A, VAN DER WEE-PALS L, CECCHINI MG, PAPAPOULOS SE, LÖWIK CW. Dissociation of angiogenesis and osteoclastogenesis during endochondral bone formation in neonatal mice. J Bone Miner Res 2002; 17: 998-1007.
21. CETINKAYA BO, KELES GC, AYAS B, GURGOR P. Effects of risedronate on alveolar bone loss and angiogenesis: A stereologic study in rats. J Periodontol 2008; 79: 1950-1961.
22. OTTO S, HAFNER S, MAST G, TISCHER T, VOLKMER E, SCHIEKER M, STÜRZENBAUM SR, VON TRESCKOW E, KOLK A, EHRENFELD M, PAUTKE C. Bisphosphonate-related osteonecrosis of the jaw: is pH the missing part in the pathogenesis puzzle? J Oral Maxillofac Surg 2010; 6: 1158-1161.
23. ROCK EP, GOODMAN V, JIANG JX, MAHJOOB K, VERBOIS SL, MORSE D, DAGHER R, JUSTICE R, PAZDUR R. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007; 12: 107-113.
24. MIGNOGNA MD, FORTUNA G, LEUCI S, POLLIO A, RUOPPO E. Sunitinib adverse event: oral bullous and lichenoid mucositis. Ann Pharmacother 2009; 43: 546-547.
25. KOLLMANNSBERGER C, SOULIERES D, WONG R, SCALERA A, GASPO R, BJARNASON G. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 2007; 1: 41-54.
26. ROSENBAUM SE, WU S, NEWMAN MA, WEST DP, KUZEL T, LACOUTURE ME. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer 2008; 16: 557-566.
27. GREUTER S, SCHMID F, RUHSTALLER T, THUERLIMANN B. Bevacizumab-Associated osteonecrosis of the jaw. Ann Oncol 2008; 19: 2091-2092.